Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07473518

Thyroid Carcinoma in Cancer Patients Undergoing Radiotherapy

This study aims to define the optimal surveillance strategy for children exposed to radiotherapy by assessing the incidence, risk factors, and timing of thyroid nodules and differentiated thyroid cancer. It also investigates the genetic features of thyroid tumors in this population to identify predictive biomarkers of onset, malignancy, and aggressiveness. Ultimately, the goal is to support more personalized management, including tailored surgery and targeted therapies.

Recruiting

Interested in participating?

Request Info

Key information

Age range

10 year–43 year

Sex eligibility

All sexes

Study type

Observational

Primary location

UO Medicina Nucleare - IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy

Loading trial locations.

About this study

This study aims to improve our understanding of how best to monitor children who have been exposed to radiotherapy, a group known to be at higher risk of developing thyroid nodules and differentiated thyroid cancer (DTC). Current pediatric guidelines are not fully consistent in defining the most appropriate surveillance strategy for these patients. By implementing an early and intensive clinical and ultrasound follow-up, the study seeks to provide clearer evidence on how frequently thyroid abnormalities occur, which factors increase the risk, and when these conditions typically arise after radiotherapy. The ultimate goal is to define a surveillance approach that enables early detection while remaining practical, cost-effective, and mindful of the emotional burden placed on young oncology patients.

Another important focus of the study is the genetic characterization of thyroid tumors in children exposed to radiotherapy. Evidence supporting the use of molecular testing in the diagnostic and therapeutic management of pediatric thyroid cancer is still limited. By analyzing genetic biomarkers in both cytological and histological samples, the study aims to explore their role in predicting the development, malignancy, and aggressiveness of thyroid tumors. These findings could help pave the way toward more personalized care, supporting more conservative surgical approaches when appropriate and facilitating the use of targeted therapies.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

For the group of oncologic patients who underwent radiotherapy:

  • Radiotherapy for an oncologic condition performed between January 1, 1999, and December 31, 2018;
  • Age at the time of radiotherapy < 18 years;
  • Follow-up of at least 4 years conducted at the Endocrine-Metabolic Diseases Program, Pediatric Unit, IRCCS AOU Bologna;
  • Obtained informed consent

For the group of subjects not exposed to radiotherapy and without specific risk factors for DTC:

  • No history of exposure to ionizing radiation;
  • No specific risk factors for DTC (autoimmune thyroiditis, familial forms, genetic syndromes);
  • Thyroid ultrasound performed between January 1, 1999, and December 31, 2018, at the Nuclear Medicine Unit of IRCCS AOU Bologna;
  • Age at the time of the thyroid ultrasound < 18 years;
  • Obtained informed consent

Exclusion criteria

For the group of oncologic patients who underwent radiotherapy:

  • Patients transferred to another center before completing 4 years of follow-up after radiotherapy at the Pediatric Unit of IRCCS AOU Bologna, without having received a diagnosis of thyroid cancer.

For the group of subjects not exposed to radiotherapy and without specific risk factors for DTC:

  • None.

Treatment and study plan

Primary outcomes

  1. To calculate the incidence of thyroid nodules and/or thyroid cancer in patients who were exposed and not exposed to radiotherapy

    Time frame: At 4 years after radiotherapy for the radiotherapy-exposed group; At the time of ultrasound for the non-radiotherapy group

    Presence of thyroid nodules and/or thyroid cancer (yes/no)

  2. "To identify risk factors for the development of thyroid nodules and/or thyroid cancer in patients who underwent radiotherapy during childhood

    Time frame: At 4 years after radiotherapy

    Presence of thyroid nodules and/or thyroid cancer (yes/no)

Secondary outcomes

  1. To identify genetic biomarkers predictive of thyroid cancer development in the pediatric population, both exposed and not exposed to radiotherapy

    Time frame: At 4 years after radiotherapy for the radiotherapy-exposed group; At the time of ultrasound for the non-radiotherapy group

    Presence of thyroid cancer (yes/no)

Study contacts

Contact information is provided by the study sponsor or research team.

Federico Baronio

CONTACT

[email protected]

00390512144816

Sponsors and collaborators

Lead sponsor

IRCCS Azienda Ospedaliero-Universitaria di Bologna

Other

Registry information

Important dates

Study start
2025
Primary completion
2026
Study completion
2027
First posted
Mar 16, 2026
Registry last updated
Mar 16, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.